Абстракт

Objectives: ●To compare the efficacy and safety of 5% minoxidil monotherapy, Redensyl–Capixyl–Procapil (RCP) monotherapy, and combination therapy of RCP and minoxidil in the treatment of androgenetic alopecia in adult males. ●To study treatment compliance and tolerability among patients using the three different therapeutic regimens. Introduction: Androgenetic alopecia (AGA) is the most common cause of patterned, non-scarring hair loss in men, mediated by dihydrotestosterone-induced follicular miniaturization. Topical 5% minoxidil is widely used but often causes local irritation, dryness, and requires long-term use for sustained benefit. Recently, Redensyl–Capixyl–Procapil (RCP), a botanical and peptide-based topical complex, has emerged as a potential alternative with multiple mechanisms of action and fewer side effects. Evidence comparing RCP to minoxidil, and assessing combined use, is limited, especially in South Asian populations. Materials / method: A hospital-based, prospective, quantitative study enrolled 96 male patients with AGA (Norwood–Hamilton grade II–V), divided equally into three groups: 5% minoxidil monotherapy, RCP monotherapy, and combination therapy (RCP morning, minoxidil night). Patients were followed for 12 months at baseline, 3, 6, 9, and 12 months. Efficacy was evaluated using the Norwood–Hamilton scale, trichoscopy, global photographic assessment, Investigator Global Assessment (IGA), and a patient self-evaluation questionnaire. Data were analyzed using ANOVA, Kruskal–Wallis, and Chi-square tests Results: After 12 months, combination therapy showed the greatest improvement in hair density, trichoscopic parameters, and overall patient satisfaction (p < 0.001). Both RCP and minoxidil monotherapies demonstrated comparable efficacy with modest improvement from baseline (p < 0.05). Investigator and patient assessments correlated strongly with objective findings. No major adverse effects were reported; mild itching and dandruff occurred in a few patients in the minoxidil group, resolving with emollient shampoo use. Conclusion: Combination therapy with Redensyl–Capixyl–Procapil and 5% minoxidil demonstrated superior efficacy and comparable safety to monotherapies. This dual approach may enhance patient satisfaction and adherence, offering an effective, well-tolerated treatment option for male androgenetic alopecia.